Figure 1 (Pravastatin Fig1)
This text presents information on the proportion of subjects without events related to Coronary Heart Disease Death or Nonfatal Myocardial Infarction. It shows survival distributions between placebo and pravastatin over a period of five years since randomization, with a significant Logrank P-value of 0.0001 highlighting the effect of pravastatin.*